Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 108

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 108
---
 the Company with 45 calendar days, or until October 25, 2024, to submit a plan to regain compliance with the minimum stockholders’ equity standard. If the Company’s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from September 10, 2024 for the Company to regain compliance.

On October 15, 2024, the Company submitted a plan to Nasdaq to regain compliance. However, there can be no assurance that the Company’s plan will be accepted or that, if it is, that the Company will be able to regain compliance and maintain its listing on the Nasdaq Capital Market. If the Company’s plan to regain compliance is not accepted or if Nasdaq does not grant an extension and the Company does not regain compliance, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In that event, the Company will have an opportunity to appeal Nasdaq’s decision to a hearings panel.

Results of Operations

Comparison of the three months ended September 30, 2024 and 2023

The following table summarizes the results of our operations:

|                                                 |     | Three Months Ended 
 September 30,      |       2024 |   |     |   |       2023 |   |     |   |     Change |   |     |     |    % |    |
|:------------------------------------------------|:----|:-------------------|-----------:|:--|:----|:--|-----------:|:--|:----|:--|-----------:|:--|:----|:----|-----:|:---|
| Revenue                                         |     | $                  |          - |   |     | $ |          - |   |     | $ |          - |   |     |     |    - |    |
| Operating expenses:                             |     |                    |            |   |     |   |            |   |     |   |            |   |     |     |      |    |
| Research and development                        |     |                    |  1,400,564 |   |     |   |  1,045,177 |   |     |   |    355,387 |   |     |     |   34 | %  |
| General and administrative                      |     |                    |    328,995 |   |     |   |